Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. - Wikidata - awgldk - TriplyDB

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

http://www.wikidata.org/entity/Q35127277

about

Targeting Cell Survival Proteins for Cancer Cell Death DangER: protein ovERload. Targeting protein degradation to treat myeloma Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage Heat shock protein 90 inhibition: rationale and clinical potential.Targeting β-tubulin:CCT-β complexes incurs Hsp90- and VCP-related protein degradation and induces ER stress-associated apoptosis by triggering capacitative Ca2+ entry, mitochondrial perturbation and caspase overactivation.Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor Bioactivities of Compounds from Elephantopus scaber, an Ethnomedicinal Plant from Southwest China.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayi Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.Macrocyclic inhibitors of hsp90 A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer Heat shock protein 90 inhibition in lung cancer.Molecular targets for tumor radiosensitization.First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90 A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.Purine-scaffold Hsp90 inhibitors.Model of translational cancer research in multiple myeloma.Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats Inhibitors of the heat shock response: biology and pharmacology.Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.Future options for imatinib mesilate-resistant tumors.Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.Preclinical studies of novel targeted therapies.A review of recent patents on the protozoan parasite HSP90 as a drug target From the bench to the bedside: emerging new treatments in multiple myeloma.

P2860

Q26765447-8F3668AA-97EE-4FD7-9B66-40D5A111722B Q26825417-8E5058AB-3284-443E-ACA9-D42BB4190248 Q27022514-DD936CFD-896D-4A1F-AA90-0942BEF3145A Q27335863-4DE464F1-F5EE-4B12-BA82-FDE1F0694E3E Q27851585-79A212E4-92EC-4007-992F-4CB4B191CA01 Q27851619-7A03D5D8-BD39-45C1-955A-FC31DEC4BA50 Q28474489-A19D30A2-E46B-41AF-940B-ED1225E4A69C Q28730558-94C73674-1B89-47E6-ADC4-53858062F3F6 Q30418761-B01C2790-26A6-4BE0-A84C-D320286C9A8B Q30532061-521C16C3-0C2A-4D72-8C7C-ED299E0DEF05 Q33330693-801490CE-A386-45C9-89F3-9474487054E3 Q33748655-94BEB694-C6CD-499C-8737-92975A8B52BF Q34164027-2139642F-5D29-4A3F-8E6F-FE450F7369C9 Q34301113-1796B32F-B042-4A4A-BD40-4759FC100E5A Q34400894-FBBA8BB7-2723-4205-8420-55095F8D3813 Q34478388-BCBB1B1E-BF8A-48A2-9DD2-EC6C17EC26B6 Q34495415-6264C9E4-05EF-4EBF-A359-6D9C48C9D227 Q34568868-521C1E2D-08EF-4D1A-BFF4-EBD2CD4693D0 Q34702338-5255E733-499A-49A1-AB19-46370D158C12 Q35017513-8570157E-4E99-4E22-8D1C-C6BA8ABE68A5 Q35089528-C92E7C0F-2CB6-4031-A6D2-45BED40C3319 Q35169884-AD7D16A7-5BCC-4D30-AA39-1D4581D44C64 Q35194754-D6A55BA7-E438-418F-BAAA-724EC89FA1C9 Q35762499-F91D89BE-5096-4C85-B53E-B54B88A2CF39 Q36126009-1EABB7F2-0C45-454D-9F74-760F85FC9610 Q36310262-DEC5D611-A810-41C4-9DAC-6426685696F4 Q36316817-738A79FB-F508-4C21-A3C0-4DC0D809B60E Q36336795-80BC107F-1CAE-426D-860A-978FD603F5EF Q36372909-B3EFB3E3-CB65-477A-BA72-273419E2820A Q36426208-FE06331A-7984-441F-951A-FE430DB1EFA4 Q36498784-F4F997E9-3DC5-4F20-92BD-F485BCF3D40B Q36802340-ED96F491-F6AF-4F54-A306-3D5EA730E023 Q36845355-56260114-9B4A-4387-94F0-5EC83B1FD84F Q36953062-FB4721DB-EE18-4980-9CBF-5D9AB3546DE2 Q36964688-8AF18F23-4B8B-421B-9CC0-D69FC0AB9597 Q36967257-B9FABDFB-349F-476E-B231-2BDA34F705C3 Q36976738-21D00E16-15BB-4326-A59E-C18B7A4832B4 Q36998210-E4A37BF2-2B67-4445-B22B-169243066DDC Q36998394-FEA20250-19D3-41AA-B29A-AB5BA0F156EE Q37028598-61C995F5-A203-4802-9963-3FDF4332920B

P2860

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

http://www.wikidata.org/entity/Q35127277

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@ast

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@en

type

label

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@ast

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@en

prefLabel

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@ast

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@en

P1433

Q35127277-E47C0900-E8DE-42B8-BD03-B239CA3A46D3

P1476

Q35127277-93AF3F0C-2EAA-44B4-801F-B9D50E7AA38D

P2093

Q35127277-0088EA0F-29BA-4D74-B74B-6CD1DEF790EC

Q35127277-068DBE12-5A41-43D5-9450-78778B62E477

Q35127277-0B751A52-ED8C-42F1-AFD1-7F20EDD04535

Q35127277-0FA6F4C6-947A-4D1E-801F-BB1223FEE7D9

Q35127277-3E7CE47F-7998-4AEF-955B-0CB10D6CB402

Q35127277-5D6DD70E-7D15-4404-81D8-8FC7BB96EF46

Q35127277-683C3A5C-6795-4ADD-BD8C-C7D423D89D8E

Q35127277-6EBD8CE7-0970-47D8-BFBB-C4888ECAEFF3

Q35127277-746FB3B8-5E4B-4A43-825B-9D59E7018FF2

Q35127277-7DC7D16A-DB11-4087-8BB2-0D76ADC05830

P2860

Q35127277-015F91D9-BB55-46A6-8E16-A478ECC78614

Q35127277-140CE2AD-3A51-4F72-B85D-A47A9E31F6BA

Q35127277-163AB0A8-AA38-4858-BDDD-365099F11706

Q35127277-1E349FF9-650D-4B17-95CE-6FB8CB3626D0

Q35127277-2378A37C-571A-44C0-BE98-C57EF8A6EB02

Q35127277-2E596992-57E1-4182-AD79-9D00F033BFE3

Q35127277-2EDD9304-FD3D-481A-932E-C02EC9765AC1

Q35127277-31AAD6AD-4038-48B7-AF5F-915E391BBE95

Q35127277-3A32949A-A54C-41E5-84F8-5FF089E5DD4E

Q35127277-492A8A6B-CE19-45A0-876C-B0ECCB67F7FC

P304

Q35127277-80E241CD-E092-4A55-9D77-E6730A6BFB08

P31

Q35127277-C7496105-4EA4-4AEE-84D7-27F7EFE14656

P356

Q35127277-D5BA1463-7152-4F56-A408-D5AB2A7D17CE

P407

Q35127277-DC9D793E-3E98-41C3-9695-97F6D35AC3D3

P433

Q35127277-2E95B713-9ECD-46E1-89A8-81BC7C1C9A6D

P478

Q35127277-377D233E-BF73-4AE1-B70F-24ABF35D9405

P577

Q35127277-165630C3-7904-4091-8FE9-E38FB30BBAF9

P5875

Q35127277-CBD06D58-4BD4-4AEB-989C-8FC598505F7E

P698

Q35127277-EF0FD506-CC3C-4E60-B602-D5837768FAEA

P921

Q35127277-DBD953D4-DEF5-4762-8AD0-6802492D5B12

P932

Q35127277-437666BA-BF74-4E3C-931B-001799E277C1

P356

PNAS.0608372103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Development of 17-allylamino-1 ...... agent directed against Hsp90.

@en

P2093

Caroline Woodward

http://www.w3.org/2001/XMLSchema#string

Christine S Pien

http://www.w3.org/2001/XMLSchema#string

Courtney Penders

http://www.w3.org/2001/XMLSchema#string

David S Grayzel

http://www.w3.org/2001/XMLSchema#string

Emmanuel Normant

http://www.w3.org/2001/XMLSchema#string

James R Porter

http://www.w3.org/2001/XMLSchema#string

Janid A Ali

http://www.w3.org/2001/XMLSchema#string

Jebecka Hudak

http://www.w3.org/2001/XMLSchema#string

Jeffrey K Tong

http://www.w3.org/2001/XMLSchema#string

Jens R Sydor

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90

NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

Molecular chaperones in cellular protein folding

HSP90 and the chaperoning of cancer

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

The Hsp90 chaperone complex as a novel target for cancer therapy.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

P304

17408-17413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0608372103

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6705952

http://www.w3.org/2001/XMLSchema#string

P698

17090671

http://www.w3.org/2001/XMLSchema#string

P921

retaspimycin hydrochloride

P932

1635022

http://www.w3.org/2001/XMLSchema#string